Association of High LAT1 Expression with Poor Prognosis and Recurrence in Colorectal Cancer Patients Treated with Oxaliplatin-Based Adjuvant Chemotherapy

被引:6
|
作者
Shibasaki, Yuta [1 ]
Yokobori, Takehiko [2 ]
Sohda, Makoto [1 ]
Shioi, Ikuma [1 ]
Ozawa, Naoya [1 ]
Komine, Chika [1 ]
Suga, Kunihiko [1 ]
Nakazawa, Nobuhiro [1 ]
Osone, Katsuya [1 ]
Shiraishi, Takuya [1 ]
Okada, Takuhisa [1 ]
Sano, Akihiko [1 ]
Sakai, Makoto [1 ]
Ogawa, Hiroomi [1 ]
Kaira, Kyoichi [3 ]
Shirabe, Ken [1 ]
Saeki, Hiroshi [1 ]
机构
[1] Gunma Univ, Grad Sch Med, Dept Gen Surg Sci, Maebashi 3718510, Japan
[2] Gunma Univ Initiat Adv Res GIAR, Div Integrated Oncol Res, Maebashi 3718511, Japan
[3] Saitama Univ Hosp, Comprehens Canc Ctr, Int Med Ctr, Dept Resp Med, Hidaka 3501298, Japan
基金
日本学术振兴会;
关键词
L-type amino acid transporter-1; cancer aggressiveness; prognostic marker; chemosensitivity marker; TRANSPORTER; FLUOROURACIL; LEUCOVORIN; LEVAMISOLE; RESISTANCE; THERAPY; ASCT2;
D O I
10.3390/ijms24032604
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The mammalian target of rapamycin (mTOR) is often activated in several cancers. We focused on two mTOR regulatory mechanisms: oxaliplatin-induced mTOR signaling and L-type amino acid transporter 1 (LAT1)-induced mTOR activation. High LAT1 expression in several cancers is associated with mTOR activation and resistance to chemotherapy. However, the significance of LAT1 has not yet been elucidated in colorectal cancer (CRC) patients treated with post-operative adjuvant chemotherapy. Immunohistochemistry was conducted to examine the significance of membrane LAT1 expression in 98 CRC patients who received adjuvant chemotherapy, including oxaliplatin. In vitro analysis was performed using CRC cell lines to determine the effects of LAT1 suppression on proliferation, oxaliplatin sensitivity, and mTOR signaling. LAT1 expression was associated with cancer aggressiveness and poor prognosis in 98 CRC patients treated with adjuvant chemotherapy. We found that positive LAT1 expression correlated with shorter survival in 43 patients treated with the capecitabine-plus-oxaliplatin (CAPOX) regimen. LAT1 suppression in CRC cells inhibited the proliferation potency and oxaliplatin-induced activation of mTOR signaling, and improved oxaliplatin sensitivity. LAT1 evaluation before adjuvant treatment may therefore be a sensitive marker for oxaliplatin-based regimens. Moreover, LAT1 may be a promising target for patients with refractory CRC.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Genetic variants as potential predictive biomarkers in advanced colorectal cancer patients treated with oxaliplatin-based chemotherapy
    Bahrami, Afsane
    Amerizadeh, Forouzan
    Hassanian, Seyed Mahdi
    ShahidSales, Soodabeh
    Khazaei, Majid
    Maftouh, Mina
    Ghayour-Mobarhan, Majid
    Ferns, Gordon A.
    Avan, Amir
    JOURNAL OF CELLULAR PHYSIOLOGY, 2018, 233 (03) : 2193 - 2201
  • [22] MGMT-535G>T POLYMORPHISM IS ASSOCIATED WITH PROGNOSIS FOR PATIENTS WITH METASTATIC COLORECTAL CANCER TREATED WITH OXALIPLATIN-BASED CHEMOTHERAPY
    Kim, J. G. K.
    Choi, G. S. C.
    Chung, H. Y. C.
    Jun, S. H. J.
    Lim, K. H. L.
    Kang, B. W. K.
    Jeon, S. W. J.
    ANNALS OF ONCOLOGY, 2010, 21 : I35 - I35
  • [23] MGMT-535G>T polymorphism is associated with prognosis for patients with metastatic colorectal cancer treated with oxaliplatin-based chemotherapy
    Park, Jee Hyun
    Kim, Nung Soo
    Park, Jae Yong
    Chae, Yee Soo
    Kim, Jong Gwang
    Sohn, Sang Kyun
    Moon, Joon Ho
    Kang, Byung Woog
    Ryoo, Hun Mo
    Bae, Sung Hwa
    Choi, Gyu Seog
    Jun, Soo-Han
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2010, 136 (08) : 1135 - 1142
  • [25] ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer
    Huang, Zhao-Hui
    Hua, Dong
    Du, Xiang
    Li, Li-Hua
    Mao, Yong
    Liu, Zhi-Hui
    Song, Ming-Xu
    Zhou, Xi-Ke
    WORLD JOURNAL OF GASTROENTEROLOGY, 2008, 14 (41) : 6401 - 6407
  • [26] Role of Calcium/Magnesium Infusion in Oxaliplatin-Based Chemotherapy for Colorectal Cancer Patients
    Kurniali, Peter C.
    Luo, Lu Guang
    Weitberg, Alan B.
    ONCOLOGY-NEW YORK, 2010, 24 (03): : 289 - 292
  • [27] Oxaliplatin-based chemotherapy in the treatment of elderly patients with metastatic colorectal cancer (CRC)
    Berretta, Massimiliano
    Zanet, Ernesto
    Nasti, Guglielmo
    Lleshi, Arben
    Frustaci, Sergio
    Fiorica, Francesco
    Bearz, Alessandra
    Talamini, Renato
    Lestuzzi, Chiara
    Lazzarini, Renzo
    Fisichella, Rossella
    Cannizzaro, Renato
    Iaffaioli, Rosario Vincenzo
    Berretta, Salvatore
    Tirelli, Umberto
    ARCHIVES OF GERONTOLOGY AND GERIATRICS, 2012, 55 (02) : 271 - 275
  • [28] Definition of oxaliplatin sensitivity in patients with advanced colorectal cancer previously treated with oxaliplatin-based therapy
    de Gramont Lesparre, A. H.
    Chibaudel, B.
    Bourges, O.
    Perez-Staub, N.
    Tournigand, C.
    Maindrault-Goebel, F.
    Andre, T.
    Larsen, A. K.
    Afchain, P.
    Louvet, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [29] DEFINITION OF OXALIPLATIN SENSITIVITY IN PATIENTS WITH ADVANCED COLORECTAL CANCER PREVIOUSLY TREATED WITH OXALIPLATIN-BASED THERAPY
    de Gramont, A.
    Chibaudel, B.
    Bourges, O.
    Perez-Staub, N.
    Tournigand, C.
    Maindrault-Goebel, F.
    Andre, T.
    Larsen, A.
    Afchain, P.
    Louvet, C.
    ANNALS OF ONCOLOGY, 2009, 20 : 13 - 13
  • [30] SLF1 polymorphism predicts response to oxaliplatin-based adjuvant chemotherapy in patients with colon cancer
    Han, Xiaohong
    Wang, Zheng
    Zhang, Lei
    Shen, Yinchen
    Tan, Qiaoyun
    Sun, Yongkun
    Wang, Jianfei
    Qian, Xiaoyan
    Yang, Hongying
    Shi, Yuankai
    AMERICAN JOURNAL OF CANCER RESEARCH, 2021, 11 (04): : 1522 - +